Published 2 years ago • loading... • Updated 2 years ago

Moderna reports RSV vaccine for older adults is 84% effective

Summary by Reuters

Moderna Inc (MRNA.O) said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.

28 Articles

All

Left

Center

Right

Philstar Global

Lean Left

Moderna reports positive results for RSV vaccine

US biotech company Moderna announced positive interim trial results for its vaccine against respiratory syncytial virus in adults over the age of 60.

2 years ago·Manila, Philippines

Read Full Article

CBS News

Lean Left

Moderna says its' RSV vaccine highly effective in older adults

Moderna has reportedly developed an RSV vaccine with the same messenger RNA technology used in its COVID-19 shot.

2 years ago

Read Full Article

Ars Technica

Center

RSV vaccine for older adults is 84% effective, Moderna says

It's another positive sign for mRNA vaccines and the fight against RSV.

2 years ago·United States

Read Full Article

Live Science

Center

Moderna says its RSV vaccine is 84% effective in older adults

Moderna announced positive results from its late-stage RSV vaccine trial in older adults.

2 years ago·United States

Read Full Article

WebMD

Center

Moderna Says RSV Vaccine for Older Adults Is 84% Effective

Moderna announced that its vaccine for respiratory syncytial virus (RSV) for older adults was 84% effective at preventing at least two symptoms of the illness and 82% effective at preventing at least three symptoms.

2 years ago·Los Angeles, United States

Read Full Article